NRIX Stock Analysis: Buy, Sell, or Hold?
NRIX - Nurix Therapeutics, Inc. Common stock
$26.72
-0.33 (-1.22%)
▼
5d:
-1.22%
30d:
+12.55%
90d:
+52.42%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 08, 2026
Get Alerted When NRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NRIX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NRIX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NRIX is currently trading at $26.72, which is considered extended relative to its 30-day fair value range of $23.12 to $26.40.
Technical Outlook: Technically, NRIX is in a strong uptrend. Immediate support is located at $25.13, while resistance sits at $28.23.
Market Sentiment: NRIX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.50 (+25.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRIX is in a strong uptrend. Immediate support is located at $25.13, while resistance sits at $28.23.
Market Sentiment: NRIX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.50 (+25.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.12 -
$26.40
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.4% below Wall St target ($33.50)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.12 -
$26.40
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$25.13
Resistance Level
$28.23
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.57
Wall Street Target
$33.50
(+25.4%)
Revenue Growth (YoY)
-79.5%
Share & Embed Analysis
Last updated: August 22, 2026 3:58 PM ET
Data refreshes hourly during market hours. Next update: 4:58 PM
Data refreshes hourly during market hours. Next update: 4:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
